QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NASDAQ:TARS

Tarsus Pharmaceuticals Stock Forecast, Price & News

$27.54
-1.46 (-5.03 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.20
$29.08
50-Day Range
$21.21
$29.68
52-Week Range
$17.96
$63.69
Volume
27,268 shs
Average Volume
33,835 shs
Market Capitalization
$566.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive TARS News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Tarsus Pharmaceuticals logo

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TARS
Employees
20
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$8.17 per share

Profitability

Net Income
$-26.81 million
Pretax Margin
-8.19%

Debt

Price-To-Earnings

Miscellaneous

Free Float
13,768,000
Market Cap
$566.50 million
Next Earnings Date
11/3/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.49 out of 5 stars

Medical Sector

130th out of 1,372 stocks

Biological Products, Except Diagnostic Industry

19th out of 197 stocks

Analyst Opinion: 3.6Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Tarsus Pharmaceuticals (NASDAQ:TARS) Frequently Asked Questions

Is Tarsus Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tarsus Pharmaceuticals stock.
View analyst ratings for Tarsus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Tarsus Pharmaceuticals?

Wall Street analysts have given Tarsus Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tarsus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Tarsus Pharmaceuticals' next earnings date?

Tarsus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Tarsus Pharmaceuticals
.

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) issued its quarterly earnings data on Wednesday, August, 4th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.52) by $0.81. The business had revenue of $22.02 million for the quarter, compared to analysts' expectations of $10 million.
View Tarsus Pharmaceuticals' earnings history
.

What price target have analysts set for TARS?

5 equities research analysts have issued 1-year price targets for Tarsus Pharmaceuticals' shares. Their forecasts range from $33.00 to $65.00. On average, they expect Tarsus Pharmaceuticals' share price to reach $46.25 in the next year. This suggests a possible upside of 67.9% from the stock's current price.
View analysts' price targets for Tarsus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Tarsus Pharmaceuticals' key executives?

Tarsus Pharmaceuticals' management team includes the following people:
  • Dr. Bobak R. Azamian M.D., Pres, CEO & Director (LinkedIn Profile)
  • Mr. Leonard M. Greenstein, Chief Financial Officer (Age 45, Pay $416.74k)
  • Dr. Seshadri Neervannan Ph.D., Chief Operating Officer (Age 53, Pay $486.67k)
  • Dr. Bryan Wahl J.D., M.D., Gen. Counsel (Age 43)
  • Ms. Maaza Martin, Director of Marketing
  • Ms. Dianne C. Whitfield, Chief HR Officer (Age 44)
  • Mr. Aziz Mottiwala, Chief Commercial Officer (Age 43) (LinkedIn Profile)
  • Mr. Michael Holdbrook, VP of Clinical Affairs (Age 68)
  • Ms. Kim Norman, Sr. Director of Fin.
  • Dr. Elizabeth Yeu Lin M.D., Chief Medical Advisor (Age 43)

When did Tarsus Pharmaceuticals IPO?

(TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

What is Tarsus Pharmaceuticals' stock symbol?

Tarsus Pharmaceuticals trades on the NASDAQ under the ticker symbol "TARS."

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tarsus Pharmaceuticals' stock price today?

One share of TARS stock can currently be purchased for approximately $27.54.

How much money does Tarsus Pharmaceuticals make?

Tarsus Pharmaceuticals has a market capitalization of $566.50 million. The company earns $-26.81 million in net income (profit) each year or ($4.32) on an earnings per share basis.

How many employees does Tarsus Pharmaceuticals have?

Tarsus Pharmaceuticals employs 20 workers across the globe.

What is Tarsus Pharmaceuticals' official website?

The official website for Tarsus Pharmaceuticals is www.tarsusrx.com.

How can I contact Tarsus Pharmaceuticals?

The company can be reached via phone at 949-409-9820 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.